Wall Street Journal @WSJ reporter covering pharmaceutical industry. Contact me at 215-881-7127, peter.loftus@wsj.com.

AbbVie Pins Hopes on Hepatitis C Treatment

wsj.com — Fresh off a failed takeover bid that would have lowered its taxes and diversified its product lineup, drug maker AbbVie Inc. is hoping for a Christmas gift: regulatory approval of its first significant new product in a decade. The North Chicago, Ill., company is awaiting a decision from the U.S.

Merck drug shrank tumors in some breast cancer patients in trial

marketwatch.com — A Merck & Co. drug shrank tumors in about 18.5% of women with an aggressive form of breast cancer in a small clinical trial, an early sign of the potential of immunotherapy to treat breast tumors. The Merck drug, Keytruda, was approved by U.S. regulators in September to treat a deadly form of skin cancer, melanoma.

Merck to Buy Cubist Pharmaceuticals for $8.4 Billion

wsj.com — Drug giant Merck & Co. agreed to buy antibiotics maker Cubist Pharmaceuticals Inc. for $8.4 billion. The deal, which also includes the assumption of $1.1 billion in debt, is worth $102 a share, a 37% premium to Friday's close. Cubist specializes in drugs to treat infectious diseases and other conditions, primarily in a hospital...

Merck to buy Cubist Pharmaceuticals for $8.4 billion

marketwatch.com — Drug giant Merck & Co. agreed to buy antibiotics maker Cubist Pharmaceuticals Inc. for $8.4 billion. The deal, which also includes the assumption of $1.1 billion in debt, is worth $102 a share, a 37% premium to Friday's close. Cubist specializes in drugs to treat infectious diseases and other conditions, primarily in a hospital setting.

Merck Nears $8 Billion Deal to Buy Cubist Pharmaceuticals

online.wsj.com — Drug giant Merck & Co. is nearing a deal to buy antibiotics maker Cubist Pharmaceuticals Inc. for more than $8 billion, people familiar with the matter said. Merck would pay about $100 per share for Cubist, one of the people said. That's roughly 34% over Cubist's closing price Friday of $74.36.

Merck obtains rights to experimental Ebola vaccine

marketwatch.com — Merck & Co. has obtained the rights to an experimental Ebola vaccine developed by NewLink Genetics Corp., another sign of the scramble by pharmaceutical companies and other groups to find new ways to combat the deadly viral outbreak centered in West Africa.

New Bristol-Myers Drug Helped Skin-Cancer Patients in Trial Live Longer

online.wsj.com — A new Bristol-Myers Squibb Co. drug helped skin-cancer patients live longer than those who received chemotherapy in a clinical trial, the latest evidence behind a promising new crop of drugs that work by unleashing the body's immune system against tumors.

Researchers to Start Studies of Two Antivirals in Ebola Patients in December

online.wsj.com — Researchers plan to start clinical trials in West Africa in December to test whether two antiviral drugs can help patients survive the deadly Ebola virus, and hope to get answers by February 2015.

Merck Filing Suggests Trial Results Won’t Significantly Hurt Vytorin, Zetia

online.wsj.com — Merck & Co. said Monday it has learned the results of a long-running clinical trial designed to answer questions about the efficacy of blockbuster cholesterol drugs Vytorin and Zetia and has determined there is no need to write down their value for accounting purposes.

Race Is On to Detect Ebola More Quickly

online.wsj.com — Kirk Ririe boarded a flight from Salt Lake City to New York on Oct. 25 with an unusual item checked into his baggage: a machine that can test whether people are infected with Ebola virus.
More Articles →
Dec 18, 2014

Global life expectancy rose by 5.8 years for men and 6.6 years for women since 1990 on.wsj.com/1sHeaaW via @WSJ pic.twitter.com/TXXTqQLJzB

Dec 18, 2014

@ac_walters It spans the Wissahickon Creek in the Valley Green section of Philadelphia's Fairmount Park.

Dec 18, 2014

RT @stefaniei: Waiting game: AbbVie pins hopes on FDA giving the nod to its hepatitis C treatment. on.wsj.com/1AqHUaU via @Loftus

Dec 16, 2014

'Thank you for sacking me' Andrew Luck’s unique brand of trash talk: over-the-top compliments on.wsj.com/1xlv28o via @WSJ

Dec 16, 2014

RT @jon_kamp: Power morcellators were around for 2 decades before #FDA warning. @TomBurtonWSJ and I write about why on.wsj.com/1wUDKe5 via @WSJ

Dec 12, 2014

RT @MarkSchoenebaum: What's your favorite stock for 2015 in biotech or Pharma?

Dec 12, 2014

RT @jonathanrockoff: Most drugs in development by category: cancer (288), CNS (130), respiratory (73), infectious disease (65), vaccines (62)-- @CowenResearch



Are You a Journalist?

Make a Portfolio

Create a free Muck Rack account to customize your profile and upload a portfolio of your best work.

Email

For instructions on how to pitch Peter Loftus, email loftus@muckrack.com.


Share This Profile